Exagen Announces Addition to Russell 3000® and 2000® Indexes
December 16 2019 - 7:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it will be added to the Russell 3000® and
2000® Indexes, effective after the US market opens on December 23,
2019. Membership in the U.S. all-cap Russell 3000® Index, which
remains in place for one year, means automatic inclusion in the
small-cap Russell 2000® Index based on Exagen’s market
capitalization. Exagen will also be added to the appropriate growth
and value style indexes.
“We are pleased to have earned inclusion in the
widely recognized Russell indexes,” said Ron Rocca, CEO of Exagen.
“This is an important milestone in Exagen’s growth, and reflects
the value the market places upon our ability to significantly
improve outcomes for patients suffering from autoimmune
diseases.”
Russell US Indexes are widely used by investment
managers and institutional investors as the basis for index funds
and as benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked against Russell US Indexes.
Russell US Indexes are part of FTSE Russell’s suite of index
offerings.
For more information on the Russell US Indexes, go
to the FTSE Russell website.
About Exagen Inc.
Exagen is dedicated to transforming the care
continuum for patients suffering from debilitating and chronic
autoimmune diseases by enabling timely differential diagnosis and
optimizing therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
InvestorsWestwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
MediaExagen Inc. Kamal
AdawiKAdawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2024 to May 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From May 2023 to May 2024